All In Biotech

Free tool

FAERS Monitor: Climara Pro

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 021258 or its brand name (Climara Pro, Estradiol, Levonorgestrel). Reports on generic versions are filed under their own applications.

Reports

2,062

Serious

253

12% of reports

Hospitalization

14

Death reported

1

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • product adhesion issue668
  • product physical issue348
  • device adhesion issue268
  • wrong technique in product usage process265
  • hot flush230
  • application site rash194
  • drug ineffective157
  • product quality issue139
  • application site pruritus110
  • application site erythema102
  • application site irritation94
  • device breakage94
  • drug dose omission87
  • wrong technique in device usage process76
  • vaginal haemorrhage73

Reports by year received

View as table
YearReports
20041
20052
20064
200713
2008104
2009106
2010110
201182
2012105
201367
201488
201597
2016118
2017239
2018159
2019101
202095
202189
202271
202390
202496
2025124
2026101

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,097 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
product adhesion issueSignal668194.3182.4126,093
device adhesion issueSignal268181.3162.047,079
product physical issueSignal348179.0162.560,428
application site rashSignal194145.9127.527,409
application site irritationSignal9477.663.76,986
application site pruritusSignal11049.741.45,180
application site erythemaSignal10239.833.03,814
hot flushSignal23031.227.66,701
device breakageSignal9423.719.42,018
vaginal haemorrhageSignal7317.213.71,097
wrong technique in device usage processSignal7616.613.31,101
wrong technique in product usage processSignal26513.411.93,042
product quality issueSignal13910.48.91,185
drug dose omissionSignal875.44.4307
drug ineffective1571.21.06

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.